NASDAQ:MDCX Medicus Pharma Q2 2025 Earnings Report $0.16 -0.01 (-4.09%) Closing price 04:00 PM EasternExtended Trading$0.16 +0.00 (+0.61%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Medicus Pharma EPS ResultsActual EPS-$0.43Consensus EPS -$0.39Beat/MissMissed by -$0.04One Year Ago EPSN/AMedicus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicus Pharma Announcement DetailsQuarterQ2 2025Date8/11/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsMedicus Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Medicus Pharma Earnings HeadlinesMedicus Pharma Narrows SkinJect Focus To Gorlin Syndrome, Drops Sporadic BCC Program3 hours ago | rttnews.comMedicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patientsSeptember 21 at 10:03 AM | proactiveinvestors.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 22 at 1:00 AM | Behind the Markets (Ad)Medicus Pharma Narrows SkinJect Development to Gorlin Syndrome in Capital-Efficient ShiftSeptember 21 at 9:31 AM | tipranks.comMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory AssessmentSeptember 21 at 8:10 AM | markets.businessinsider.comMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory AssessmentSeptember 21 at 7:30 AM | globenewswire.comSee More Medicus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicus Pharma and other key companies, straight to your email. Email Address About Medicus PharmaMedicus Pharma (NASDAQ:MDCX). is a life sciences company focused on the development, acquisition and commercialization of pharmaceutical and medical technologies. The company’s activities are centered primarily on specialty healthcare markets, including dermatology, wound care and medical aesthetics. Medicus Pharma seeks to advance products and therapies intended to address underserved clinical needs and to expand access to innovative treatments. Its portfolio may include internally developed and acquired products, with commercialization efforts directed toward healthcare providers and patients in markets where the company has appropriate regulatory and distribution capabilities. The company is based in Canada and trades on the Nasdaq Capital Market under the symbol MDCX. Publicly available information about its current product portfolio, geographic reach and leadership team is limited.View Medicus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
